Noven Pharmaceuticals rated buy, Jefferies says

Noven Pharmaceuticals Inc. was rated buy with a $20.00 price target by Jefferies & Co., Inc. analysts David H. Windley and Himanshu Rastogi. They added that the company's hormone therapy franchise, which includes Vivelle/Vivelle-Dot and CombiPatch, is on track to meet the forecast. Noven shares closed Thursday down $0.37, or 2.17%, at $16.71 on volume of 126,350 shares compared to a three-month trailing average of 166,541 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.